News
Actival and Neuria receive CHF 40’000 from Venture Kick
Actival and Neuria Digital Therapeutics were selected at Venture Kick’s second financial and entrepreneurial support stage. Actival: 3D printing a novel generation of active dental aligners Clear dental aligners have recently caused one of the biggest disruptions in the dental industry. They are a transparent and removable alternative to traditional metal braces and…
Read MoreFour Swiss Health Valley biotech companies worth keeping an eye out for in 2024
Labiotech.eu, a leading digital media covering the European Biotech industry, published a list of Swiss biotech companies to put on your radar. Switzerland is home to a thriving biotech industry, with strong research institutions many companies leading the way in cutting-edge research for new cancer treatments and immunotherapies, from startups to multinationals. Labiotech highlighted…
Read MoreConsulto secures CHF 400’000 Innosuisse Innovation Grant
EPFL startup, Consulto, has been awarded a CHF 400’000 grant in collaboration with EPFL, CHUV, the University of Basel, and Groupe Mutuel to revolutionise patient care pathway design and implementation. This new funding represents a significant milestone for the startup as it accelerates the development of ConsultoPATH. An AI pathway designer that helps…
Read MoreThe Patient Quality of Life Challenge announced its finalists
Supported by Debiopharm, La-Solution.ch and the Inartis Foundation, the aim of this award is to support a selection of projects over a 4-month period to enable prototypes to be developed and produced. At the end of the year, the winner (or co-winners) whose prototype is judged to be the best will receive a prize of…
Read MoreiOnctura announces €80 Million Series B
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, announced that it has closed an €80 Million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital,…
Read MoreHekeTiss gets CHF 100’000 seed loan from FONGIT Innovation Fund (FIF)
The FONGIT Innovation Fund (FIF) in Geneva has awarded new funding to three cutting-edge tech projects including HekeTiss. UNIGE and HUG spinoff HekeTiss, an award-winning startup, has secured a Seed Loan of CHF 100’000, building on their previous FIF Grant of CHF 50,000 awarded in 2022. HekeTiss has developed trophiPatch, an innovative treatment…
Read MoreAktiia receives regulatory approval
Aktiia, the Swiss startup revolutionizing Blood Pressure (BP) monitoring and management, announces it has received regulatory approval (CE mark) for its next-generation optical technology that does not require calibration with a traditional cuff. The CE mark allows market access to potentially over 40 countries. The underlying groundbreaking calibration-free technology, known as CALFREE™, uses…
Read MoreINCAPTEK wins Exhibitors’ Grand Prix at EPHJ
The 2024 Exhibitors’ Grand Prix was awarded to Incaptek, a Jura-based company, for its cutting-edge new technology for producing ultra-resistant composite materials. EPHJ, the international high-precision trade show, closed the doors of its 22nd edition with record attendance and a quality of Swiss and international trade visitors praised by the 765 exhibitors. During…
Read MoreWyss Center reported a new breakthrough in brain monitoring
Research teams at the Wyss Center in partnership with, Inselspital unveiled a groundbreaking long-term EEG system that facilitates continuous monitoring of brain activity in real-life settings. This innovative technology has the potential to revolutionise epilepsy treatment and advance understanding of various neurological disorders. Current practice in clinical neurophysiology is limited to short recordings…
Read MoreOculis just announced positive topline results of phase 2b RELIEF Trial
Oculis, announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED). The Phase 2b RELIEF trial is a multi-centre, randomised, double-masked, vehicle-controlled trial evaluating the efficacy and safety…
Read More